288
Participants
Start Date
December 1, 2022
Primary Completion Date
November 30, 2024
Study Completion Date
November 30, 2027
Nimotuzumab
"Drug: Nimotuzumab Experimental: Nimotuzumab arm Induction chemotherapy:Nimotuzumab 200mg will be given weekly for 6 cycles, started on day 1 of induction chemotherapy.~Concurrent chemotherapy: Nimotuzumab 200mg/week in concurrent with IMRT. Adjuvant therapy: Nimotuzumab (200mg ) will be given every 3 weeks for 8 cycles.~Active Comparator: Control Nimotuzumab 200mg/week in concurrent with IMRT ."
Gemcitabine
Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 2 cycles
Cisplatin
"Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles.~Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles."
Intensity-modulated radiotherapy
Definitive IMRT of 68-78 Gy, 30-33 fractions, 5 fractions/week, 1 fraction/day
RECRUITING
Second Affiliated Hospital of Guangzhou Medical University, Nanjing
RECRUITING
People's Hospital of Baise, Baise City
RECRUITING
Affiliated Hospital of Youjiang Medical University for Nationalities, Baise City
RECRUITING
The First People's Hospital of Qinzhou, Qinzhou
RECRUITING
Guilin Medical University, China, Guilin
RECRUITING
Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin
RECRUITING
Wuzhou Red Cross Hospital, Wuzhou
RECRUITING
Liuzhou People's Hospital, Liuzhou
RECRUITING
the Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou
People's Hospital of Baise
UNKNOWN
Second Affiliated Hospital of Guangzhou Medical University
OTHER
People's Hospital of Guangxi Zhuang Autonomous Region
OTHER
Guilin Medical University, China
OTHER
LiuZhou People's Hospital
OTHER
The First People's Hospital of Qinzhou
UNKNOWN
Wuzhou Red Cross Hospital
OTHER
Youjiang Medical College for Nationalities
OTHER
Fourth Affiliated Hospital of Guangxi Medical University
OTHER